CAI
Caris Life Sciences, Inc. (CAI)
Healthcare • Biotechnology • $16.49 • MCap: 4,661,404,672
🌐
https://www.carislifesciences.com • Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Buy Decision Core
Total Score
49
Business Quality
10
Financial Strength
20
Growth Outlook
1
Momentum
3
Price Action
Current
16.49
52W High
39.30
52W Low
14.55
Above 50DMA
17.00 (-3.02%)
Above 200DMA
22.42 (-26.46%)
Relative Strength
Relative Strength
-0.33
RS 3M
-0.19
RS 6M
-0.38
RS 9M
-0.46
RS 12M
-0.42
Fundamentals
Revenue Growth
0.79%
Earnings Growth
0%
ROE
0.28%
ROA
0.09%
Valuation
PE (Fwd)
46.36
PEG
0
P/B
7.85
Upside
63.74%
Risk
Beta
0
Short %
0.12
Risk Score
9.00
Analyst
Rating
buy
Target
27.00
Beta
0
Analysts
0
Total Score
49
Upside
63.74%
Relative Strength
-0.33
Beta
0
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Analyst upside exceeds 15%
Key Risks
- Weak long-term relative strength
Score Breakdown
Business
10
10
Financial
20
20
Growth
1
1
Valuation
6
6
Risk
3
3
Momentum
3
3
Technical
52W High: 39.30
52W Low: 14.55
Above 50DMA: -3.02%
Above 200DMA: -26.46%
Valuation
Forward PE: 46.36
PEG: 0
P/B: 7.85
Upside: 63.74%
Risk
Beta: 0
Short Float: 0.12%
ROE: 0.28%
ROA: 0.09%